OpGen

OpGen CROIC

The Cash Return on Invested Capital (CROIC) of OpGen (OPGN) as of Oct 27, 2026 is -3.51 %. In the previous year, Cash Return on Invested Capital (CROIC) was -65.98 % — a change of -94.68% (higher).

CROIC

-3.51 %

YoY

-94.68%

Last updated:

Cash Return on Invested Capital (CROIC) of OpGen is 2025 -3.51 % . Cash Return on Invested Capital (CROIC) of OpGen was 2024 -65.98 % . It decreases by -94.68% higher compared to the previous year.

The OpGen CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-215.63 USD
Jan 1, 2019
-127.49 USD
Jan 1, 2020
-53.42 USD
Jan 1, 2021
-35.34 USD
Jan 1, 2022
-93.87 USD
Jan 1, 2023
-1,020.16 USD
Jan 1, 2024
-65.98 USD
Jan 1, 2025
-3.51 USD
The OpGen CROIC history
YEARCROICYoY
-3.51 %-94.68%
-65.98 %-93.53%
-1,020.16 %+986.80%
-93.87 %+165.63%
-35.34 %-33.85%
-53.42 %-58.10%
-127.49 %-40.88%
-215.63 %-60.12%
-540.64 %+40.72%
-384.19 %+142.28%
-158.58 %-241.06%
112.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Cash Return on Invested Capital (CROIC) of OpGen is -3.51 % in 2025.

Cash Return on Invested Capital (CROIC) of OpGen changed from -65.98 % to -3.51 %, representing a -94.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) OpGen since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s OpGen with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — OpGen

All Key Metrics — OpGen